SynOx Therapeutics Secures $75m For Phase 3 TGCT Treatment Trial
SynOx Therapeutics has concluded a successful $75 million Series B financing, led by Forbion, HealthCap, and Bioqube Ventures. The funding will be instrumental in advancing emactuzumab, a potentially groundbreaking CSF-1(R) inhibiting monoclonal antibody, into Phase 3 clinical trials for treating Tenosynovial Giant Cell Tumour (TGCT), a debilitating condition affecting major joints. Emactuzumab has shown promising results in earlier clinical studies, boasting a 71% objective response rate and significant improvements in functional ability, indicating its potential as a next-generation therapy for TGCT. The addition of experienced professionals like Dr. Carlo Incerti and Jon Edwards to the Board of Directors underscores SynOx's commitment to advancing emactuzumab and addressing unmet medical needs, marking a transformative phase for the company as it accelerates late-stage clinical development.
Ray Barlow, CEO of SynOx Therapeutics, expressed enthusiasm, stating that the funding will allow the generation of registrational data for emactuzumab in TGCT, providing a much-needed option for patients suffering from this grievous disease. Dirk Kersten of Forbion and Jon Edwards of Bioqube Ventures also expressed excitement about the potential of emactuzumab to deliver best-in-class results and highlighted SynOx's strategic focus on addressing underserved medical needs, while Ton Logtenberg emphasized the validation of SynOx's strategy and the crucial role of the new board members in driving forward cutting-edge therapies for rare diseases.
Comments
Post a Comment